Marken Appoints New Vice President, Global Quality Assurance

Dr. Navnit Patel to Focus on Expanding the Company's Market-Leading Quality Systems

RESEARCH TRIANGLE PARK, N.C.Feb. 20, 2018 /PRNewswire/  Marken is pleased to announce the appointment of Navnit Patel, Ph.D., as Vice President, Global Quality Assurance, effective March 05, 2018. Dr. Patel will focus on enhancing Marken's industry-leading quality systems and set new standards for the movement and storage of clinical trial materials.  Marken's ongoing quality initiatives include: implementation of a recently updated Quality Management System (QMS), expansion of the company's own Good Distribution Practice (GDP) certification program, and adding increased capabilities to its electronic document management system.  These quality initiatives are designed to complement the systems and standards of Marken's pharmaceutical clients and are expected to establish new standards for quality in the clinical trial logistics industry.  

During his 23-year career, Dr. Patel served in various quality management positions with leading global pharmaceutical and biotech companies, including: DuPont-Merck, Bristol Myers Squibb, DSM, Schering Plough, Merck, Johnson & Johnson, Novartis, and most recently as Director of Quality Assurance & Quality Control for Rutgers University Cells and DNA Repository-Infinite Biologics.  Dr. Patel holds a Ph.D. in Organic Chemistry, has published over 20 research papers in internationally recognized journals and is a certified Lean Six Sigma Black Belt.

Wes Wheeler, Chief Executive Officer, commented, "Navnit is a seasoned quality leader who brings to Marken a wealth of experience, energy and expertise in pharmaceutical quality assurance, quality control and quality systems management. We are excited to have Navnit join our management team and look forward to his leadership as we take our quality management systems to a whole new level."

SOURCE Marken

 

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

Q: